Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Xilio Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 29 | 1 | 28 | 0 |
| Shares | 16.6M | 667.7K | 15.9M | −12.9K (−0.1%) |
| Value | $48.3M | $1.94M | $42.8M | −$3.54M (−7.6%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Trustees of Columbia University in the City of New York | 249,635 | $672.0K | 1.39% |
| Bank of America Corp | 233,068 | $627.0K | 0.00% |
Sold out (2)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ergoteles LLC | 12,941 | $38.0K |
| RBF Capital, LLC | 10,072 | $29.0K |
Not filed for Q4 2022 yet (1)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AJU IB Investment Co., Ltd. | 667,742 | $1.94M |